Rituximab for the therapy of systemic sclerosis: a series of 10 cases in a single center
Autor(a) principal: | |
---|---|
Data de Publicação: | 2016 |
Outros Autores: | , , , , |
Tipo de documento: | Relatório |
Idioma: | eng |
Título da fonte: | Revista Brasileira de Reumatologia (Online) |
Texto Completo: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0482-50042016000500458 |
Resumo: | Abstract Systemic sclerosis (SSc) is a chronic autoimmune disease with a high morbidity and mortality. Although cyclophosphamide is effective for severe and refractory cases, there is demand for new treatments. The biological treatment with B-cell depletion with rituximab (RTX) has demonstrated efficacy for this demand in open-label studies. Objective This study was conducted with the aim to retrospectively evaluate all patients who used RTX for the treatment of SSc in our center. Patients and methods We retrospectively evaluated medical records of all patients with SSc who used RTX to treat this disease from January 2009 to January 2015. Systemic, cutaneous, and pulmonary involvement data and laboratory results before and six months after the first infusion of RTX were collected. Results Ten patients received treatment during the study period and were included in this series. All patients had a diffuse form of the disease. Five patients suffered from an early (duration of disease shorter or equal to four years), rapidly progressive disease, and another five received RTX at late stages of the disease. In both groups of patients, stabilization of the pulmonary picture was observed, with a fall in the skin score in those patients with early forms of the disease. Discussion Similar to findings in previous studies, RTX was effective in treating early and rapidly progressive forms of SSc. We also found that patients with long-term illness may benefit from the treatment. |
id |
SBR-1_031e643d0fde586deb8bab008e6305be |
---|---|
oai_identifier_str |
oai:scielo:S0482-50042016000500458 |
network_acronym_str |
SBR-1 |
network_name_str |
Revista Brasileira de Reumatologia (Online) |
repository_id_str |
|
spelling |
Rituximab for the therapy of systemic sclerosis: a series of 10 cases in a single centerSystemic sclerosisRituximabPulmonary fibrosisModified Rodnan skin scoreAbstract Systemic sclerosis (SSc) is a chronic autoimmune disease with a high morbidity and mortality. Although cyclophosphamide is effective for severe and refractory cases, there is demand for new treatments. The biological treatment with B-cell depletion with rituximab (RTX) has demonstrated efficacy for this demand in open-label studies. Objective This study was conducted with the aim to retrospectively evaluate all patients who used RTX for the treatment of SSc in our center. Patients and methods We retrospectively evaluated medical records of all patients with SSc who used RTX to treat this disease from January 2009 to January 2015. Systemic, cutaneous, and pulmonary involvement data and laboratory results before and six months after the first infusion of RTX were collected. Results Ten patients received treatment during the study period and were included in this series. All patients had a diffuse form of the disease. Five patients suffered from an early (duration of disease shorter or equal to four years), rapidly progressive disease, and another five received RTX at late stages of the disease. In both groups of patients, stabilization of the pulmonary picture was observed, with a fall in the skin score in those patients with early forms of the disease. Discussion Similar to findings in previous studies, RTX was effective in treating early and rapidly progressive forms of SSc. We also found that patients with long-term illness may benefit from the treatment.Sociedade Brasileira de Reumatologia2016-10-01info:eu-repo/semantics/reportinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0482-50042016000500458Revista Brasileira de Reumatologia v.56 n.5 2016reponame:Revista Brasileira de Reumatologia (Online)instname:Sociedade Brasileira de Reumatologia (SBR)instacron:SBR10.1016/j.rbre.2016.06.003info:eu-repo/semantics/openAccessVilela,Verônica SilvaMaretti,Giselle BaptistaGama,Lívia Marques da SilvaCosta,Claudia Henrique daRufino,Rogério LopesLevy,Roger A.eng2016-10-20T00:00:00Zoai:scielo:S0482-50042016000500458Revistahttp://www.scielo.br/scielo.php?script=sci_serial&pid=0482-5004&lng=pt&nrm=isoONGhttps://old.scielo.br/oai/scielo-oai.php||sbre@terra.com.br1809-45700482-5004opendoar:2016-10-20T00:00Revista Brasileira de Reumatologia (Online) - Sociedade Brasileira de Reumatologia (SBR)false |
dc.title.none.fl_str_mv |
Rituximab for the therapy of systemic sclerosis: a series of 10 cases in a single center |
title |
Rituximab for the therapy of systemic sclerosis: a series of 10 cases in a single center |
spellingShingle |
Rituximab for the therapy of systemic sclerosis: a series of 10 cases in a single center Vilela,Verônica Silva Systemic sclerosis Rituximab Pulmonary fibrosis Modified Rodnan skin score |
title_short |
Rituximab for the therapy of systemic sclerosis: a series of 10 cases in a single center |
title_full |
Rituximab for the therapy of systemic sclerosis: a series of 10 cases in a single center |
title_fullStr |
Rituximab for the therapy of systemic sclerosis: a series of 10 cases in a single center |
title_full_unstemmed |
Rituximab for the therapy of systemic sclerosis: a series of 10 cases in a single center |
title_sort |
Rituximab for the therapy of systemic sclerosis: a series of 10 cases in a single center |
author |
Vilela,Verônica Silva |
author_facet |
Vilela,Verônica Silva Maretti,Giselle Baptista Gama,Lívia Marques da Silva Costa,Claudia Henrique da Rufino,Rogério Lopes Levy,Roger A. |
author_role |
author |
author2 |
Maretti,Giselle Baptista Gama,Lívia Marques da Silva Costa,Claudia Henrique da Rufino,Rogério Lopes Levy,Roger A. |
author2_role |
author author author author author |
dc.contributor.author.fl_str_mv |
Vilela,Verônica Silva Maretti,Giselle Baptista Gama,Lívia Marques da Silva Costa,Claudia Henrique da Rufino,Rogério Lopes Levy,Roger A. |
dc.subject.por.fl_str_mv |
Systemic sclerosis Rituximab Pulmonary fibrosis Modified Rodnan skin score |
topic |
Systemic sclerosis Rituximab Pulmonary fibrosis Modified Rodnan skin score |
description |
Abstract Systemic sclerosis (SSc) is a chronic autoimmune disease with a high morbidity and mortality. Although cyclophosphamide is effective for severe and refractory cases, there is demand for new treatments. The biological treatment with B-cell depletion with rituximab (RTX) has demonstrated efficacy for this demand in open-label studies. Objective This study was conducted with the aim to retrospectively evaluate all patients who used RTX for the treatment of SSc in our center. Patients and methods We retrospectively evaluated medical records of all patients with SSc who used RTX to treat this disease from January 2009 to January 2015. Systemic, cutaneous, and pulmonary involvement data and laboratory results before and six months after the first infusion of RTX were collected. Results Ten patients received treatment during the study period and were included in this series. All patients had a diffuse form of the disease. Five patients suffered from an early (duration of disease shorter or equal to four years), rapidly progressive disease, and another five received RTX at late stages of the disease. In both groups of patients, stabilization of the pulmonary picture was observed, with a fall in the skin score in those patients with early forms of the disease. Discussion Similar to findings in previous studies, RTX was effective in treating early and rapidly progressive forms of SSc. We also found that patients with long-term illness may benefit from the treatment. |
publishDate |
2016 |
dc.date.none.fl_str_mv |
2016-10-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/report |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
report |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0482-50042016000500458 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0482-50042016000500458 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
10.1016/j.rbre.2016.06.003 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
text/html |
dc.publisher.none.fl_str_mv |
Sociedade Brasileira de Reumatologia |
publisher.none.fl_str_mv |
Sociedade Brasileira de Reumatologia |
dc.source.none.fl_str_mv |
Revista Brasileira de Reumatologia v.56 n.5 2016 reponame:Revista Brasileira de Reumatologia (Online) instname:Sociedade Brasileira de Reumatologia (SBR) instacron:SBR |
instname_str |
Sociedade Brasileira de Reumatologia (SBR) |
instacron_str |
SBR |
institution |
SBR |
reponame_str |
Revista Brasileira de Reumatologia (Online) |
collection |
Revista Brasileira de Reumatologia (Online) |
repository.name.fl_str_mv |
Revista Brasileira de Reumatologia (Online) - Sociedade Brasileira de Reumatologia (SBR) |
repository.mail.fl_str_mv |
||sbre@terra.com.br |
_version_ |
1750318051468771328 |